This page contains brief information about everolimus and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Everolimus is approved to treat:
- Breast cancer. It is used in combination with exemestane in postmenopausal women with advanced hormone receptor–positive (HR+) breast cancer that is also HER2 negative (HER2-) and has not gotten better after treatment with letrozole or anastrozole.
- Pancreatic cancer, gastrointestinal cancer, and lung cancer (certain types). It is used in adults with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body).
- Renal cell carcinoma (a type of kidney cancer) that is advanced, in adults who have not gotten better after treatment with sunitinib or sorafenib.
Subependymal giant cell astrocytoma in adults and children aged 1 year or older who have tuberous sclerosis and are not able to have surgery.
The use of everolimus to treat cancer is approved for the Afinitor and Afinitor Disperz brands. Everolimus is also approved to treat transplant rejection. This use is approved for the Zortress brand.
Everolimus is also being studied in the treatment of other types of cancer.
More About Everolimus
MedlinePlus Information on Everolimus – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.